These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 24330023)

  • 41. Treatment of painful bone lesions and hypercalcemia.
    Ascari E; Attardo-Parrinello G; Merlini G
    Eur J Haematol Suppl; 1989; 51():135-9. PubMed ID: 2534078
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1: Mechanisms of action, role of biomarkers and preclinical applications.
    Saba N; Khuri F
    Oncology; 2005; 68(1):10-7. PubMed ID: 15775688
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bisphosphonates in multiple myeloma.
    Apperley JF; Croucher PI
    Pathol Biol (Paris); 1999 Feb; 47(2):178-81. PubMed ID: 10192885
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Effects of pamidronate disodium (Bonin) combined with chemotherapy on bone pain in multiple myeloma].
    Leng Y; Chen SL; Shi HZ
    Space Med Med Eng (Beijing); 2002 Oct; 15(5):377-8. PubMed ID: 12449148
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications.
    Hirsh V; Tchekmedyian NS; Rosen LS; Zheng M; Hei YJ
    Clin Lung Cancer; 2004 Nov; 6(3):170-4. PubMed ID: 15555218
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
    J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases.
    Saad F; Chen YM; Gleason DM; Chin J
    Clin Genitourin Cancer; 2007 Sep; 5(6):390-6. PubMed ID: 17956712
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Myeloma: diagnosis complications and supportive care.
    Morgan G
    Hematology; 2012 Apr; 17 Suppl 1():S109-11. PubMed ID: 22507795
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.
    Rosen LS; Gordon D; Tchekmedyian NS; Yanagihara R; Hirsh V; Krzakowski M; Pawlicki M; De Souza P; Zheng M; Urbanowitz G; Reitsma D; Seaman J
    Cancer; 2004 Jun; 100(12):2613-21. PubMed ID: 15197804
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Zoledronic acid: past, present and future roles in cancer treatment.
    Saad F
    Future Oncol; 2005 Apr; 1(2):149-59. PubMed ID: 16555985
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mechanisms behind the anti-tumour effects of zoledronic acid use in multiple myeloma.
    Ararat E; Sahin I; Ozdemir E; Altundag K
    Br J Haematol; 2010 Dec; 151(5):530-1. PubMed ID: 20880117
    [No Abstract]   [Full Text] [Related]  

  • 52. Oral bisphosphonates: A review of clinical use in patients with bone metastases.
    Major PP; Lipton A; Berenson J; Hortobagyi G
    Cancer; 2000 Jan; 88(1):6-14. PubMed ID: 10618600
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bisphosphonate therapy in multiple myeloma.
    Laakso M; Jantunen E
    Acta Oncol; 1996; 35 Suppl 5():55-6. PubMed ID: 9142966
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term effects of parenteral dichloromethylene bisphosphonate (CL2MBP) on bone disease of myeloma patients treated with chemotherapy.
    Merlini G; Parrinello GA; Piccinini L; Crema F; Fiorentini ML; Riccardi A; Pavesi F; Novazzi F; Silingardi V; Ascari E
    Hematol Oncol; 1990; 8(1):23-30. PubMed ID: 2137106
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma.
    Henk HJ; Teitelbaum A; Perez JR; Kaura S
    Am J Hematol; 2012 May; 87(5):490-5. PubMed ID: 22454220
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma.
    Baulch-Brown C; Molloy TJ; Yeh SL; Ma D; Spencer A
    Leuk Res; 2007 Mar; 31(3):341-52. PubMed ID: 16996129
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.
    Kohno N; Aogi K; Minami H; Nakamura S; Asaga T; Iino Y; Watanabe T; Goessl C; Ohashi Y; Takashima S
    J Clin Oncol; 2005 May; 23(15):3314-21. PubMed ID: 15738536
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.
    Lacy MQ; Dispenzieri A; Gertz MA; Greipp PR; Gollbach KL; Hayman SR; Kumar S; Lust JA; Rajkumar SV; Russell SJ; Witzig TE; Zeldenrust SR; Dingli D; Bergsagel PL; Fonseca R; Reeder CB; Stewart AK; Roy V; Dalton RJ; Carr AB; Kademani D; Keller EE; Viozzi CF; Kyle RA
    Mayo Clin Proc; 2006 Aug; 81(8):1047-53. PubMed ID: 16901028
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review.
    Weide R; Koppler H; Antras L; Smith M; Chang MP; Green J; Wintfeld N; Neary MP; Duh MS
    J Cancer Res Ther; 2010; 6(1):31-5. PubMed ID: 20479544
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma.
    Avilés A; Nambo MJ; Neri N; Castañeda C; Cleto S; Huerta-Guzmán J
    Med Oncol; 2007; 24(2):227-30. PubMed ID: 17848748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.